This funding adds to the approximately $67 million the company raised in October 2020. Proceeds will be used to advance the company's pipeline into clinics and to scale up global business operations.
This year, the company's lead candidate, an investigational CRISPR/Cas9 gene editing therapy for patients with transfusion dependent beta-thalassemia, was the first hematopoietic stem cell therapy investigational new drug application approval in China. The company is also preparing to initiate a trial for other drug candidates, including allogeneic chimeric antigen receptor (CAR) T-cell therapy and in vivo therapies based on an RNA base editing technology called leveraging endogenous ADAR for programmable editing of RNA (LEAPER).
The series B plus financing round was led by Loyal Valley Capital.
Copyright © 2021 scienceboard.net